Lawrence Blonde, MD
- Sr Physician-NV, Southshore Region
- 1514 Jefferson Hwy, New Orleans, LA, 70121
For additional information or to make an appointment, click here.
Overview
Overview
- Dr. Blonde graduated from Albany Medical College in New York, where also completed his internship, residency and endocrinology fellowship. He is board certified in internal medicine, nuclear medicine, and endocrinology and has been on staff at Ochsner since 1974. Among his many other professional responsibilities, Dr. Blonde serves as Director of the Ochsner Diabetes Clinical Research Unit, and is an Associate of Internal Medicine Residency Program Director. Dr. Blonde is chair of the Steering Committee of National Diabetes Education Program (NDEP), a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations working to "change the way diabetes is treated." He is also a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE)
Publications
Selected publications
-
2023American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm-2023 Update. Endocrine Practice. 29:305-340.
-
2022Editorial Cycles and Continuity of Diabetes Care. Diabetes Care. 45:1493-1494.
-
2020A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care. 44:8-10.
-
2020Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L. Diabetes Therapy. 11:1007-1015.
-
2020Hypoglycaemia is reduced with use of inhaled Technosphere (R) Insulin relative to insulin aspart in type 1 diabetes mellitus. Diabetic Medicine. 37:752-759.
-
2019Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care. 42:1136-1146.
-
2019Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study. Diabetes, Obesity and Metabolism. 21:1596-1605.
-
2019Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Current Medical Research and Opinion. 35:793-804.
-
2019Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes, Obesity and Metabolism. 21:2384-2393.
-
2018A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Current Medical Research and Opinion. 34:1143-1152.
-
2018Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care. 41:1327-1329.
-
2018Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, Obesity and Metabolism. 20:921-929.
-
2018Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in Therapy. 35:939-965.
-
2018Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations (vol 35, pg 939, 2018). Advances in Therapy. 35:966-966.
-
2018From Randomized Controlled Trials to the Real World: Putting Evidence into Context. Journal of Family Practice. 67:S55-S60.
-
2018Impact of type 2 diabetes duration on response to iGlarLixi vs iGlar: a subanalysis of LixiLan-L. Diabetologia. 61:S386-S386.
-
2018Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 35:1763-1774.
-
2018Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. Diabetes, Obesity and Metabolism. 20:1722-1731.
-
2018Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy. 9:1347-1358.
-
2018REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS. Diabetes Technology & Therapeutics. 20:A137-A138.
-
2018Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes, Obesity and Metabolism. 20:1293-1297.
-
2018The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. Current Medical Research and Opinion. 34:1501-1511.
-
2018Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin. Diabetes Therapy. 9:1169-1184.
-
2017Diabetes Care: "Taking It to the Limit One More Time". Diabetes Care. 40:3-6.
-
2017Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology. 16.
-
2017Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diabetes and Vascular Disease Research. 14:172-183.
-
2017Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. Diabetes Research and Clinical Practice. 133:150-158.
-
2017Lixisenatide as add-on treatment among patients with different beta-cell function levels as assessed by HOMA-beta index. Diabetes/Metabolism Research and Reviews. 33.
-
2017NEWER LONG-ACTING BASAL INSULIN PREPARATIONS. Endocrine Practice. 23:13-17.
-
2017Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials. Diabetes, Obesity and Metabolism. 19:275-283.
-
2017The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios. JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY. 7:21-27.
-
2016A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research. 16.
-
2016Diabetes Care: "Lagniappe" and "Seeing Is Believing"!. Diabetes Care. 39:1069-1071.
-
2016Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine. 128:371-380.
-
2016Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". Diabetes Care. 39:664-667.
-
2016Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme. Diabetes, Obesity and Metabolism. 18:707-710.
-
2016Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation. 36:293-303.
-
2015Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion. 31:1993-2000.
-
2015Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clinical Therapeutics. 37:1045-1054.
-
2015Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. Diabetologia. 58:S354-S355.
-
2015Efficacy and safety of canagliflozin by baseline HbA(1c) and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications. 29:438-444.
-
2015Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Diabetes, Obesity and Metabolism. 17.
-
2015Status of Diabetes Care: New Challenges, New Concepts, New MeasuresFocusing on the Future!. Diabetes Care. 38:1177-1180.
-
2015
-
2014Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin. American Journal of Managed Care. 20:S16-S26.
-
2014
-
2014Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. American Journal of Managed Care. 20:S296-S305.
-
2014Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors. Postgraduate Medicine. 126:172-189.
-
2014FIXED-DOSE COMBINATION THERAPY IN TYPE 2 DIABETES MELLITUS. Endocrine Practice. 20:1322-1332.
-
2014Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Diabetologia. 57:S344-S344.
-
2014
-
2014IDENTIFYING RISK FACTORS FOR SEVERE HYPOGLYCEMIA IN HOSPITALIZED PATIENTS WITH DIABETES. Endocrine Practice. 20:1051-1056.
-
2014Influence of Baseline Glycemia on Outcomes With Insulin Glargine Use in Patients Uncontrolled on Oral Agents. Postgraduate Medicine. 126:111-125.
-
2014Status of Diabetes Care: "It Just Doesn't Get Any Better ... or Does It?". Diabetes Care. 37:1782-1785.
-
2014
-
2013
-
2013Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. Diabetes Care. 36:3517-3525.
-
2013THE ROLE OF BROMOCRIPTINE-QR IN THE MANAGEMENT OF TYPE 2 DIABETES EXPERT PANEL RECOMMENDATIONS. Endocrine Practice. 19:100-106.
-
2013
-
2012Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus. The American Journal of the Medical Sciences. 343:17-20.
-
2012CURRENT ISSUES IN GLP-1 RECEPTOR AGONIST THERAPY FOR TYPE 2 DIABETES. Endocrine Practice. 18:6-26.
-
2012Comparative Effectiveness of Basal-Bolus Versus Premix Analog Insulin on Glycemic Variability and Patient-Centered Outcomes during Insulin Intensification in Type 1 and Type 2 Diabetes: A Randomized, Controlled, Crossover Trial. Journal of Clinical Endocrinology and Metabolism. 97:3504-3514.
-
2012Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes, Obesity and Metabolism. 14:20-32.
-
2012Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects. Journal of the American Heart Association. 1.
-
2012Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Advances in Therapy. 29:1-13.
-
2012
-
2010Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus. American Journal of Medicine. 123:S12-S18.
-
2010Efficacy and goal attainment with insulin glargine vs comparators. Diabetologia. 53.
-
2009A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 29:1280-1288.
-
2009Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2:1-10.
-
2009Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes, Obesity and Metabolism. 11:978-986.
-
2009Diabetes treatment satisfaction in a 20-week, randomized, controlled trial (TITRATE STUDY). Diabetologia. 52:S381-S381.
-
2009Glycaemic outcomes 1 year after initiation of insulin glargine or detemir in type 2 diabetes in the US. Diabetologia. 52:S350-S351.
-
2009Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovascular Diabetology. 8.
-
2009Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE(TM) study. Diabetes, Obesity and Metabolism. 11:623-631.
-
2009The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes, Obesity and Metabolism. 11:26-34.
-
2009Therapy Situation, control of metabolism in geriatric patients with type 2 diabetes: a prospective Study. Wiener Klinische Wochenschrift. 121:S7-S7.
-
2009What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research. 6:283-287.
-
2008Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial. Diabetes Research and Clinical Practice. 79:230-236.
-
2008Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: Aripiprazole versus standard of care. Journal of Clinical Psychiatry. 69:741-748.
-
2008The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera (R) as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. Diabetic Medicine. 25:662-670.
-
2008